SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 51.08-2.1%3:35 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (1113)5/18/2000 4:27:00 PM
From: Lighthouse  Read Replies (1) of 52153
 
Peter - A question

"Seriously, though, I think spinning out the royalties would be a fantastic idea, and I have no doubt it would increase the overall market cap that INCY enjoys at present."

Interesting proposition. In my overall INCY valuation model the most sensitive input number (derived from a laundry list of assumptions) is the overall NPV of the patent portfolio. Any movement on this if akin to hitting the outer arms of a mobile. The whole thing starts moving around. I imagine this is what happenedd today.

Do you feel that spinning this off as a separate entity will allow more clarity on this piece and hence a better valuation? Or are the patent rights sold off via a "Bowie Bond" type offering and thereby getting a higher overall valuation? What do you use the cash for - if you already have $700,000,000 in the bank?

To date I have always thought that retaining the patent rights increased the overall value of INCY. A highly tangible, albeit indeterminant, pure profit stream made INCY a guaranteed genomics/pharma player in the long run. How would spinning this out be of benefit?

This is not a theological position of mine and I am happy to be "shown the light" if I have been wrong.

Cheers,
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext